MPM Oncology Impact Management »

Dbv Technologies Sa shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Dbv Technologies Sa (DBVT) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Dbv Technologies Sa

Tip: Access up to 7 years of quarterly data

All positions including Dbv Technologies Sa held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dbv Technologies Sa by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $11M 1.1M 10.00
2025-06-30 $9.6M 1.1M 9.15

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Dbv Technologies Sa

Baker Bros. Advisors
Vivo Capital
MPM Oncology Impact Management
Octagon Capital Advisors
Yiheng Capital
Dr. Jeffrey R. Jay, M.D.
Adage Capital Partners GP
Millennium Management
Artisan Partners Limited Partnership
Nan Fung Trinity
Barclays
DLD Asset Management
Citadel Advisors
Morgan Stanley
Two Sigma Investments

View all funds holding Dbv Technologies Sa